Prentiss Smith & Co’s Biogen BIIB Stock Holding History

Prentiss Smith & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-385	Closed	-$136K	–	79
2018 Q3	$136K	Hold	385	–	–	0.08%	73
2018 Q2	$112K	Hold	385	–	–	0.07%	82
2018 Q1	$105K	Hold	385	–	–	0.06%	90
2017 Q4	$123K	Hold	385	–	–	0.06%	87
2017 Q3	$121K	Hold	385	–	–	0.07%	80
2017 Q2	$104K	Buy	385 +50	+15%	+$13.2K	0.05%	89
2017 Q1	$92K	Hold	335	–	–	0.05%	92
2016 Q4	$95K	Hold	335	–	–	0.06%	86
2016 Q3	$105K	Hold	335	–	–	0.06%	91
2016 Q2	$81K	Hold	335	–	–	0.05%	100
2016 Q1	$87K	Hold	335	–	–	0.05%	99
2015 Q4	$103K	Hold	335	–	–	0.05%	93
2015 Q3	$98K	Hold	335	–	–	0.05%	93
2015 Q2	$135K	Hold	335	–	–	0.07%	76
2015 Q1	$141K	Hold	335	–	–	0.07%	81
2014 Q4	$114K	Buy	+335	New	+$108K	0.05%	95

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Prentiss Smith & Co's BIIB Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Biogen (BIIB) in Q4 2018, closing a stake of 385 shares — an estimated $136K sold.

Prentiss Smith & Co first reported a position in BIIB in Q4 2014 and held it in 16 quarters. The position peaked at $141K in Q1 2015. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Prentiss Smith & Co reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 385 Biogen shares in Q4 2018, an estimated $136K.
Prentiss Smith & Co first reported a position in Biogen in Q4 2014 and held it in 16 quarters.
Prentiss Smith & Co's Biogen position peaked at $141K in Q1 2015.
1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.